Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Lowers Price Target to $290
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and lowers the price target from $320 to $290.
Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and lowers the price target from $320 to $290.